VERRICA PHARMACEUTICAL

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

09 May 2023 07:30:01 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma

12 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

11 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

06 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference

28 Feb 2023 16:05:01 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum

27 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

21 Feb 2023 07:22:36 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

24 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions

04 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results

07 Nov 2022 16:05:02 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference

31 Aug 2022 16:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results

11 Aug 2022 07:30:01 By Nasdaq GlobeNewswire

Verrica Announces Pricing of Public Offering of Common Stock

29 Jun 2022 21:23:50 By Nasdaq GlobeNewswire

Verrica Announces Proposed Public Offering of Common Stock

29 Jun 2022 16:01:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum

28 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC

24 May 2022 20:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results

09 May 2022 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

07 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

05 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results

02 Mar 2022 16:05:00 By Nasdaq GlobeNewswire